rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children
Status: Recruiting

The goal of the clinical study is to clarify the course of common congenital, infectious, and non-infectious diseases in children living in Uzbekistan, and to develop methods for their treatment and rehabilitation.

The main questions it aims to answer:

Analysis of common congenital diseases among children;
Analysis of commonly diagnosed bronchopulmonary and cardiovascular diseases among children;
Based on the results of the primary research, common diseases among children will be identified;
Analysis of existing treatment methods and their effectiveness;
Development of modern methods of treatment and rehabilitation of children.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  children from birth to 15 years; children permanently residing in the territory where the clinical examination is carried out; children included in the group of "frequently ill children"; patients without severe chronic diseases.  Exclusion Criteria:  Teenagers over 15 years old; Patients with severe neurological and mental diseases; Patients with endocrinological diseases; Patients with long-term chronic somatic diseases; Children without genetic pathologies. - HealthyVolunteers: No - Gender: All - MinimumAge: 3 Days - MaximumAge: 15 Years - StdAgeList: Child
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
Status: Recruiting

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

Eligibility:
- EligibilityCriteria: Key Inclusion Criteria:  Participants must meet all of the following inclusion criteria:  Primary diagnosis of recurrent MDD or persistent MDD. Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening and must be willing and able to continue with current antidepressant medication(s). Participants must be willing and able to comply with all study procedures and restrictions.  Key Exclusion Criteria:  Participants will be excluded from the study if they meet any of the following criteria:  Participant is pregnant or breastfeeding or plan to become pregnant during the study. Participant has an unstable medical condition or unstable chronic disease. Participant has a history of neurological abnormalities. Participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than MDD. Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy. Participant has an alcohol or substance use disorder.  Note: Other inclusion/exclusion criteria may apply - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
Status: Recruiting

To get a better insight into the central conducting lymphatic system in adult volunteers with Noonan Syndrome (NS) without clinical symptoms or signs of lymphatic disease compared to NS and CardioFacioCutaan syndrome patients with severe lymphatic disease

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Noonan Syndrome confirmed by genetic test with a class 4 or 5 pathogenic variant according to ClinVar 18 years and older (no restriction for sex) Willing and able to have MR lymphangiography scanning in the Radboudumc Oral and written informed consent None of the exclusion criteria  Exclusion Criteria:  unsuitable for MRI (e.g. metallic objects in the body, severe claustrophobia)  A history of symptoms related to lymphatic disease pregnancy renal insufficiency liver cirrhosis History of surgery related to cardiovascular disease with hemodynamic consequence Other genetic diseases - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
Status: Recruiting

To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age ≥18 years; Signed written informed consent; A diagnosis of RRMS according to the 2017 Revisions of the McDonald Criteria; High clinical and magnetic resonance imaging (MRI) inflammatory disease activity (at least 2 clinical relapses, or one clinical relapse with gadolinium (Gd)- enhancing or new T2 MRI lesions at a separate time point, in the previous 12 months) Patients referred for pharmacological treatment with aHSCT, alemtuzumab or ocrelizumab /ofatumumab, according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria and guidelines and recommendations from the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE);  Exclusion Criteria:  Diagnosis of PPMS or SPMS according to the 2017 McDonald criteria Known intolerances/allergies to the active substance or the excipients contained in the DMT and/or contraindications according to product information - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: A total of 30 male or female prospective patients with RRMS who, from clinical practice, may be referred for treatment with aHSCT, alemtuzumab or ocrelizumab/ofatumumab will be recruited. Treatment choice will be independent of participation in the study and should not be initiated with the aim of including the patient in the study. All patients will be required to sign an informed consent before the collection of data and biological material. - SamplingMethod: Non-Probability Sample
The Effects of Inspiratory Pressures on Diaphragmatic Contraction in People After Stroke
Status: Not yet recruiting

This is a cross-sectional study to determine the optimal inspiratory muscle training (IMT) intensity for stroke survivors. Participants will breathe through a pressure threshold inspiratory loading device with varying loads in random order. Each IMT intensity protocol consists of 10 breaths. During the test, accessory inspiratory muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography. Repeated-measures ANOVA will be used for statistical analysis to determine the most effective training intensity for future study.

Eligibility:
- EligibilityCriteria: Recruitment of participants after a stroke:  The inclusion criteria are:  clinical diagnosis of ischemic and/or hemorrhagic stroke. age ≥ 18 years. duration of stroke ranges from 1 month to 12 months after diagnosis. had no facial palsy, which could prevent proper labial occlusion. had not undergone thoracic or abdominal surgery. could understand and follow the verbal instruction. stable cardiac conditions. no previous history of respiratory problems.  The exclusion criteria are:  acute myocardial infarction or acute heart failure. acute pain on chest or abdominal. with the clinical signs of significant pulmonary disease. consciousness impaired. patient with nasal feeding tube, tracheal tube and/or any condition, which prevent the measurement or training.  Recruitment of healthy participants:  The inclusion criteria are:  age ≥ 18 years. had not undergone thoracic or abdominal surgery. no previous history of respiratory problems.  The exclusion criteria are:  acute myocardial infarction or acute heart failure. acute pain in the chest or abdominal. with the clinical signs of significant pulmonary disease. unstable hypertension, arrhythmias, or unstable cardiovascular conditions, such as fluctuations in blood pressure and heart rate, indicate poor cardiac prognosis or the need for vasopressor medications. pregnant. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult - StudyPopulation: People after stroke and healthy adults - SamplingMethod: Probability Sample
Efficacy of Extracorporeal Shockwave Therapy on Ultrasonography Changes of Upper Trapezius Myofascial Trigger Points in Patients With Non Specific Neck Pain
Status: Not yet recruiting

this study will be conducted to investigate the effect of Extracorporeal Shockwave Therapy on Ultrasonography Changes of Upper Trapezius Myofascial Trigger Points in Patients With Non Specific Neck Pain

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Sixty patients receiving a diagnosis of non-specific neck pain with upper trapezius myofascial trigger points by an orthopaedist physician. Body mass index of participants was normal less than (30 kg/m2)(Al-asadi, 2018). Age over 18 years. Presence of taught band. Presence of hyper irritable spot in a taught band, and reproduction of the typical referred pain pattern of the myofascial trigger point in response to compression  Exclusion Criteria:  Having signs and symptoms of neurological disorders that cause nerve root compression. Headache as a consequence of specific headache diagnosis. Having a history of specific signs of malignancy, or infection. Having a history of trauma with or without proven structural disorders in the region of the neck, shoulder, and head (e.g. whiplash). Having signs and symptoms of cerebrovascular insufficiency. Having a severe chronic disease of the locomotor system (e.g. polyarthritis, muscular disease Any participant with contraindications to shock wave therapy - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Clinical Trial to Evaluate MDW for Early Detection of Sepsis
Status: Recruiting

This study is intended to clinically verify Monocyte Distribution Width (MDW) parameter of DxH 900 Hematology Analyzer for use in early detection and risk assessment of sepsis, severe sepsis, and septic shock in critically ill patients in Emergency Department (ED). This study is also aimed to provide study supporting data for the product to be marketed in China.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult subjects (18-89 years) presenting to ED. CBC with Differential performed upon presentation as part of standard of care. Subject scheduled for at least 12 hours follow-up during ED (or inpatient, if admitted to the hospital) visit Signed the informed consent form  Exclusion Criteria:  Subjects previously enrolled in this study (i.e., re-enrollment to this study is not allowed). The subject is discharged from the hospital within 12 hours after ED visit - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 89 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients of any race and ethnicity can be enrolled to this study. Patients with a prior chronic immunosuppressive disease and subjects with hematological malignancy can also be enrolled. This study requires at least 250 sepsis subjects and 1,100 non-sepsis subjects. - SamplingMethod: Non-Probability Sample
Pericapsular Nerve Block and Iliopsoas Fascial Plane Block in Hip Surgery
Status: Recruiting

This prospective randomized interventional study aims to compare the effects of two peripheral nerve blocks, the periencapsular nerve block (PENG) and iliopsoas block (IPB), on analgesia and motor function after hip surgery.

The main questions it aims to answer are the effectivity of postoperative pain management the preservation of motor movement.

Participants will receive standardized general anesthesia and postoperative PENG or IPB in either Group.

Researchers will compare the total amount of rescue analgesia and numeric rating scale with accompanying evaluating motor function at the same time intervals within 24 hour.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients eligible for inclusion in this study were those aged 18 to 90 years who had undergone total hip arthroplasty surgery and had an American Society of Anesthesiologists (ASA) Physical Status classification of I to III and body mass index (BMI) between 18 and 30 kg/m2.  Exclusion Criteria:  Patients were excluded if they had one of the following criteria: refusal to participate, a history of neurological deficits or neuropathy affecting the lower extremity, infection at the site of block application, coagulopathy; allergy to local anaesthetics, epilepsy or treatment with antipsychotics; abuse of alcohol or drugs; previous surgery distorting the anatomy of the inguinal or supra inguinal areas; severe organ dysfunction ( kidney, liver and other); uncooperative patients who fail to respond reliably to verbal pain assessment. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)
Status: Recruiting

Migraine is the third most prevalent disease and the leading reason of years lived with disability in the most productive years of the life. Migraine associated disability can be alleviated by acute and preventive treatment. The migraine landscape has changed recently, with the approval of novel acute treatments, including oral Calcitonin gene-related peptide antagonists, the gepants (Rimegepant, Ubrogepant, Zavegepant) and 5-HT-1F antagonists, the Ditans (Lasmiditan). These have joined Triptans as acute "migraine-specific" drugs.

The TRIDIGEP study will be an open-label, multiple attack, prospective cohort study.

This study aims to describe 1) the effectiveness of the acute treatments of migraine attacks in routine clinical practice, 2) the tolerability of the drugs, and 3) to explore potential response and tolerability predictors.

The endpoints recommended by the International Headache Society will be employed, including: 1) Pain freedom; 2) Absence of the most bothersome symptom; 3) Sustained pain freedom; 4) Total freedom from migraine; 5) Headache relief; 6) Duration of attacks; 7) Time lost due to an attack; 8) Need of rescue medication. The study endpoints will be assessed at 2, 8 and 24 hours after the acute drug use. Data will be collected by the patients themselves, with a validated data collection instrument within a RedCap questionnaire, using QR codes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Fulfill the criteria for migraine, according to the International Classification of Headache Disorders, 3rd version; Treatment with triptans, Lasmiditan or Gepants as acute therapies according to their responsible physician criteria under routine clinical practice criteria; Participant have a smartphone, tablet, or computer with an internet connection; Participant accept to participate and sign the informed consent form  Exclusion Criteria:  Patient have a concomitant use of opioids, barbiturates, or ergot derivates; Participant have major cognitive or psychiatric disorder; Participants are unable to describe the result of the employed drug Participants have an insufficient proficiency of the local languages. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study population will be adult patients with migraine, according to the International Headache Society criteria. Eligible patients will be trained in the use of the data collection instruments. They will be asked to record the study variables whenever they use the investigated drug products, for at least one attack, but ideally for every attack that they use the drug, ideally for at least five different attacks. - SamplingMethod: Non-Probability Sample
Value Of ACE Index (Albumin, CRP And Endoscopy) In Predicting Intra Venous Steroid Response In Acute Severe Ulcerative Colitis In Assiut University Hospitals
Status: Not yet recruiting

Determine if the ACE index can predict resoponse to I V steroid in Acute severe ulcerative colitis
identify on admission a high-risk population who may beneft from earlier second line medical treatment or surgical intervention. ( steroid non responder groups )

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  - Adult Patients (≥18 years) known ulcerative colitis presented with activity .  2- newly diagnosed ulcerative colitis  Exclusion Criteria:  1) patient presented with CMV colitis 2) Clostridium difficile infection 3) Elective admission - Gender: All - MinimumAge: 18 Years - MaximumAge: 50 Years - StdAgeList: Adult - StudyPopulation: Pt above 18 years old presented with Acute severe ulcerative colitis treated by Iv steroid - SamplingMethod: Probability Sample
Comparison of Postoperative Pain Score Between Perioperative Intravenous Ketamine and Placebo in Patients Undergoing Unilateral Total Knee Arthroplasty Under General Anesthesia
Status: Recruiting

The goal of this clinical trial is to compare postoperative pain score between perioperative intravenous ketamine and placebo in patients undergoing unilateral total knee arthroplasty under general anesthesia. The main question[s] it aims to answer are:

Can perioperative intravenous ketamine reduce postoperative pain score during rest and movement at 0, 2, 4, 8, 12, 18, 24 hours better than no administration of Ketamine in patients undergoing Unilateral total knee arthroplasty under general anesthesia?
Can perioperative intravenous ketamine reduce morphine consumption in postoperative 24 hours, length of hospital stay, first time to receive opioid and side effect or complication from ketamine and opioid better than no administration of Ketamine in patients undergoing Unilateral total knee arthroplasty under general anesthesia? Participants will receive intravenous ketamine intraoperative TKA and comparison group will receive placebo that is normal saline. Researchers will compare perioperative intravenous ketamine and placebo to see postoperative pain score, morphine consumption in postoperative 24 hours, length of hospital stay, first time to receive opioid and side effect or complication from ketamine and opioid.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  A patient undergo unilateral total knee arthroplasty under General anesthesia at Chomthong Hospital Chiang Mai During 2024 to December 2025 Age is more than 18 years old ASA (American society of anesthesiologist) status are I,I,III A patient can cooperate in research  Exclusion Criteria:  Patients allergic to local anesthetic agent Patient who has contraindication to use ketamine Patients has coagulopathy. Injection site is infected. Patients with chronic pain received painkillers for more than 3 months. The patient has a history of opioid use. The patient has a history of alcohol dependence. Patients allergic to fentanyl or morphine. Patient who has unstable cardiovascular disease Patient who has increase intracranial pressure and high ocular pressure Pregnancy The patient who has communication problems cannot describe the level of pain The patient refused to participate in the study. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult
Physical Impairments in Elderly Individuals
Status: Not yet recruiting

There are no studies in the literature reporting the dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals. The aims of this observational study are; 1) to evaluate dyspnea, posture, strength, physical activity, functional mobility and balance in elderly individuals, 2) to reveal the relationships between these parameters of research group.

Eligibility:
- EligibilityCriteria: Inclusion Criteria for Elderly Individuals  Being 65 years or older Volunteering to participate in the study Getting a score of 23 or higher on the Standardized Mini Mental State Test  Exclusion Criteria for Elderly Individuals  - The participant has a cognitive, neurological or orthopedic disease that would affect the participant's ability to move independently and understand the questions. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 65 Years - StdAgeList: Older Adult - StudyPopulation: At least 50 individuals aged 65 and over will be included - SamplingMethod: Non-Probability Sample
Thoracoabdominal Aortic Aneurysms
Status: Not yet recruiting

Evaluation of the effectiveness of the different modalities for treatment of thoracoabdominal aortic aneurysms. FEVAR and BEVAR devices are widely used now due to its feasability and wide range of use . We aim to evaluate the effectiveness of these new devices in the management of TAAA

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  all adult consecutive patients presenting with TAAA larger than 5.5 cm  Exclusion Criteria:  active infection Asymptomatic patients with small aneurysms Allergy to contrast agents - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Adult patients - SamplingMethod: Non-Probability Sample
Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
Status: Not yet recruiting

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c. QM in US Black/African American and Hispanic participants with established ASCVD and elevated levels of Lp(a) who are treated for cardiovascular (CV) risk factors according to local practice/guidelines for the reduction of cardiovascular risk.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male and female US Black/African American and US Hispanic participants 18 to ≤ 80 years of age Lp(a) ≥ 125 nmol/L at the screening visit, measured at the Central laboratory On Standard of Care (SoC) therapy for risk factors other than Lp(a), including LDL-C (LDL-C lowering therapy dose stable for at least 30 days), elevated blood pressure and diabetes, at the randomization visit according to local practice/guidelines.  Established ASCVD disease defined as documented:  Coronary heart disease (CHD) and/or Cerebrovascular disease (CVD) and/or Peripheral arterial disease (PAD):  Exclusion Criteria:  Uncontrolled hypertension Heart failure New York Heart Association (NYHA) class IV History of malignancy of any organ system History of hemorrhagic stroke or other major bleeding Platelet count <140,000 per mm3 Active liver disease or hepatic dysfunction Significant kidney disease Pregnant or nursing women - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult